ITMI20061918A1 - Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln - Google Patents

Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln

Info

Publication number
ITMI20061918A1
ITMI20061918A1 IT001918A ITMI20061918A ITMI20061918A1 IT MI20061918 A1 ITMI20061918 A1 IT MI20061918A1 IT 001918 A IT001918 A IT 001918A IT MI20061918 A ITMI20061918 A IT MI20061918A IT MI20061918 A1 ITMI20061918 A1 IT MI20061918A1
Authority
IT
Italy
Prior art keywords
transdermic
sln
given
active ingredients
containing active
Prior art date
Application number
IT001918A
Other languages
English (en)
Inventor
Gasco
Original Assignee
Nanovector S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanovector S R L filed Critical Nanovector S R L
Priority to IT001918A priority Critical patent/ITMI20061918A1/it
Priority to US12/444,388 priority patent/US20100028432A1/en
Priority to EP07848805A priority patent/EP2083803A2/en
Priority to PCT/IB2007/002971 priority patent/WO2008041116A2/en
Publication of ITMI20061918A1 publication Critical patent/ITMI20061918A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
IT001918A 2006-10-06 2006-10-06 Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln ITMI20061918A1 (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT001918A ITMI20061918A1 (it) 2006-10-06 2006-10-06 Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln
US12/444,388 US20100028432A1 (en) 2006-10-06 2007-10-05 Formulations of active principles incorporated in slns suitable for transdermal administration
EP07848805A EP2083803A2 (en) 2006-10-06 2007-10-05 Formulations of active principles incorporated in slns suitable for transdermal administration
PCT/IB2007/002971 WO2008041116A2 (en) 2006-10-06 2007-10-05 Formulations of active principles incorporated in slns suitable for transdermal administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001918A ITMI20061918A1 (it) 2006-10-06 2006-10-06 Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln

Publications (1)

Publication Number Publication Date
ITMI20061918A1 true ITMI20061918A1 (it) 2008-04-07

Family

ID=39166746

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001918A ITMI20061918A1 (it) 2006-10-06 2006-10-06 Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln

Country Status (4)

Country Link
US (1) US20100028432A1 (it)
EP (1) EP2083803A2 (it)
IT (1) ITMI20061918A1 (it)
WO (1) WO2008041116A2 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075147C (en) 2009-04-30 2022-06-21 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
WO2015117001A1 (en) 2014-01-31 2015-08-06 Zeltiq Aesthetics, Inc. Compositions, treatment systems and methods for improved cooling of lipid-rich tissue
US9468626B2 (en) * 2014-03-13 2016-10-18 Chiesi Farmaceutici S.P.A. Melatonin-based formulations for parenteral administration
US20180271767A1 (en) * 2017-03-21 2018-09-27 Zeltiq Aesthetics, Inc. Use of saccharides for cryoprotection and related technology

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
US5250236A (en) * 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
FR2754454B1 (fr) * 1996-10-10 1998-11-27 Oreal Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same

Also Published As

Publication number Publication date
WO2008041116A3 (en) 2009-03-12
EP2083803A2 (en) 2009-08-05
WO2008041116A2 (en) 2008-04-10
US20100028432A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
DK2120878T3 (da) Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
EP2223703A4 (en) EXTERNAL PREPARATION COMPOSITION COMPRISING FATTY ACID-BASED IONIC LIQUID AS ACTIVE INGREDIENT
IT1393045B1 (it) Composizioni contenenti monogliceridi di acidi organici da c1 a c7 e glicerolo, loro preparazione ed uso come antibatterici in zootecnia.
PL1981915T3 (pl) Kompozycje składników aktywnych
BRPI0919552A2 (pt) Formulações de glifosato contendo surfactantes e amidoalquilamina
EP2036565A4 (en) PREPARATION FOR EXTERNAL APPLICATION TO THE SKIN WITH TRITERPENIC ACID
EG26306A (en) Installations and tools for the delivery of compounds to arthropods and microorganisms
EP2433631A4 (en) ANTI-INFLAMMATORY COMPOSITION CONTAINING MACROLACTIN A AND DERIVATIVE THEREOF AS ACTIVE INGREDIENTS
MY159492A (en) Solid pharmaceutical formulation with delayed release
EP2316449A4 (en) STABLE PHARMACEUTICAL COMPOSITION WITH TRANEXAMIC ACID AND ASCORBIC ACID
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
IL192328A (en) Walls of yeast cells for the treatment and protection of plants against diseases caused by pathogenic factors and compounds containing these walls of yeast cells
MY165645A (en) Cleansing composition with decyl and coco glucosides
HK1199217A1 (en) Topical pharmaceutical composition including active agents
ITMI20061918A1 (it) Formulazioni adatte ad essere somministrate per via transdermica contenenti principi attivi incorporati in sln
PL2164941T3 (pl) Sposób formulacji zapachowych składników aktywnych, dla ich ochrony i wydłużenia czasu ich oddziaływania
GB0703933D0 (en) Improvements in or relating to medicinal compositions
ITRM20060346A1 (it) Composizioni ad attivita' antigerminativa processi per ottenere dette composizioni e loro impiego
IT1391663B1 (it) Uso di composti atti ad inibire l' attivita' dell'enzima 5alfa-reduttasi e composizioni farmaceutiche e cosmetiche che li contengono
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
ITMI20062254A1 (it) Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
IL182835A0 (en) Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
GB2416287B (en) Novel methods of delivering active ingredients to plants
IT1394921B1 (it) Uso di composti come principi attivi per migliorare l'azione di riparazione cellulare dell'epidermide umana, e composizioni farmaceutiche e cosmetiche che li contengono